Key Points
- Michael Shafer sold 10,725 shares at an average price of $600 for proceeds of $6.435 million, reducing his stake by 36.41% to 18,731 shares.
- Thermo Fisher beat expectations, reporting $5.79 EPS versus $5.50 and $11.12 billion in revenue versus $10.90 billion, and issued FY2025 guidance of $22.60–$22.86 while authorizing a $5 billion share buyback.
- Analysts remain largely bullish with 19 Buys and five Holds, an average price target of $601.65, and several recent target increases into the $635–$654 range.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) EVP Michael Shafer sold 10,725 shares of the company's stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the transaction, the executive vice president owned 18,731 shares in the company, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Thermo Fisher Scientific Price Performance
Shares of TMO stock opened at $593.41 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm has a market cap of $222.95 billion, a price-to-earnings ratio of 34.28, a PEG ratio of 3.27 and a beta of 0.82. The stock has a 50-day moving average price of $544.05 and a 200 day moving average price of $477.35.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analysts' expectations of $10.90 billion. During the same quarter in the previous year, the company earned $5.28 EPS. Thermo Fisher Scientific's revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 9.94%.
Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its stock is undervalued.
Institutional Trading of Thermo Fisher Scientific
A number of hedge funds and other institutional investors have recently made changes to their positions in TMO. Financial Management Network Inc. increased its stake in Thermo Fisher Scientific by 3.7% in the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company's stock valued at $248,000 after buying an additional 18 shares during the last quarter. Bruce G. Allen Investments LLC increased its position in shares of Thermo Fisher Scientific by 8.8% in the third quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company's stock valued at $114,000 after acquiring an additional 19 shares during the last quarter. White Pine Capital LLC boosted its position in Thermo Fisher Scientific by 3.2% during the third quarter. White Pine Capital LLC now owns 611 shares of the medical research company's stock valued at $296,000 after purchasing an additional 19 shares during the last quarter. Elevation Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company's stock worth $37,000 after purchasing an additional 20 shares in the last quarter. Finally, Hopwood Financial Services Inc. raised its position in Thermo Fisher Scientific by 9.1% during the third quarter. Hopwood Financial Services Inc. now owns 239 shares of the medical research company's stock worth $116,000 after acquiring an additional 20 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
TMO has been the topic of several analyst reports. Cowen reiterated a "buy" rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an "overweight" rating in a research note on Thursday, October 23rd. TD Cowen raised their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a "buy" rating in a research report on Thursday, October 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, October 9th. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $601.65.
Check Out Our Latest Analysis on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
